β-Spaglumic acid

β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (Ki=1 μM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus) . β-Spaglumic acid can be used in neuroprotection-related studies[1][2].

Product Specifications

CAS Number

[4910-46-7]

Product Name Alternative

β-NAAG; β-N-Acetylaspartylglutamic acid

UNSPSC

12352211

Target

Aminopeptidase; mGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/β-spaglumic-acid.html

Purity

99.97

Solubility

H2O : ≥ 100 mg/mL

Smiles

O=C(O)CC[C@@H](C(O)=O)NC(C[C@@H](C(O)=O)NC(C)=O)=O

Molecular Formula

C11H16N2O8

Molecular Weight

304.25

References & Citations

[1]Yourick DL, et al. N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res. 2003 Nov 21;991 (1-2) :56-64. |[2]Wroblewska B, et al. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J Neurophysiol. 2001 Mar;85 (3) :1097-106.